Literature DB >> 20541694

Grappling with the androgen receptor: a new approach for treating advanced prostate cancer.

Timothy C Thompson1.   

Abstract

In this issue of Cancer Cell, Andersen et al. report on a small molecule that interacts with and blocks transactivation of the androgen receptor amino-terminal domain. This agent can overcome the shortcomings of clinically used antiandrogens, an important advance in the development of effective therapy for advanced prostate cancer. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 20541694      PMCID： PMC3929402          DOI： 10.1016/j.ccr.2010.05.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Authors:  Raymond J Andersen; Nasrin R Mawji; Jun Wang; Gang Wang; Simon Haile; Jae-Kyung Myung; Kate Watt; Teresa Tam; Yu Chi Yang; Carmen A Bañuelos; David E Williams; Iain J McEwan; Yuzhou Wang; Marianne D Sadar
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

3.  Androgen receptor abnormalities in castration-recurrent prostate cancer.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

4.  Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand.

Authors:  M E Van Dort; D M Robins; B Wayburn
Journal:  J Med Chem       Date:  2000-08-24       Impact factor: 7.446

Review 5.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

6.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

Review 7.  Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Authors:  Mary-Ellen Taplin; Steven P Balk
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

8.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.

Authors:  Mara P Steinkamp; Orla A O'Mahony; Michele Brogley; Haniya Rehman; Elizabeth W Lapensee; Saravana Dhanasekaran; Matthias D Hofer; Rainer Kuefer; Arul Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Diane M Robins
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

Review 9.  Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Authors:  André N Vis; Fritz H Schröder
Journal:  BJU Int       Date:  2009-06-24       Impact factor: 5.588
  9 in total
  1 in total

Review 1.  Recent progress in targeting cancer.

Authors:  Zoya N Demidenko; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.